mitoxantrone has been researched along with Leukemia L 1210 in 45 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response curve was represented by a second-degree polynomial without absolute term." | 1.31 | Effect of acetyl-L-carnitine on leukemia L1210 resistant to mitoxantrone. ( Mĕlka, M; Niang, M, 2000) |
| "Mitoxantrone (MTO) was incorporated into small unilamellar liposomes by formation of a complex between the anticancer drug and negatively charged lipids." | 1.28 | Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ( Berger, DP; Berger, MR; Fiebig, HH; Schwendener, RA, 1991) |
| "Thus, the fresh human tumors and P-388 leukemia cells in vitro were better predictors than the established cell lines for the activity of these anthracene compounds in vivo against mouse tumors." | 1.27 | New antitumor agents containing the anthracene nucleus. ( Alberts, DS; Dorr, RT; Einspahr, J; Milton, S; Remers, WA; Tunget, CL; Wunz, TP, 1987) |
| " Distribution and half-life data provide a pharmacological rationale for the use of mitoxantrone on an intermittent dosing schedule." | 1.27 | Pharmacology of mitoxantrone: mode of action and pharmacokinetics. ( Alberts, DS; Bowden, GT; Dalton, WS; Mackel, C; Peng, YM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (53.33) | 18.7374 |
| 1990's | 14 (31.11) | 18.2507 |
| 2000's | 6 (13.33) | 29.6817 |
| 2010's | 1 (2.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zee-Cheng, RK | 3 |
| Podrebarac, EG | 1 |
| Menon, CS | 1 |
| Cheng, CC | 3 |
| Agbandje, M | 1 |
| Jenkins, TC | 1 |
| McKenna, R | 1 |
| Reszka, AP | 1 |
| Neidle, S | 2 |
| Krapcho, AP | 4 |
| Getahun, Z | 2 |
| Avery, KL | 1 |
| Vargas, KJ | 1 |
| Hacker, MP | 5 |
| Spinelli, S | 1 |
| Pezzoni, G | 1 |
| Manzotti, C | 1 |
| Martelli, S | 1 |
| Dzieduszycka, M | 1 |
| Stefanska, B | 1 |
| Bontemps-Gracz, M | 1 |
| Borowski, E | 1 |
| Collier, DA | 1 |
| Showalter, HD | 3 |
| Angelo, MM | 1 |
| Berman, EM | 1 |
| Kanter, GD | 1 |
| Ortwine, DF | 1 |
| Ross-Kesten, SG | 1 |
| Sercel, AD | 1 |
| Turner, WR | 2 |
| Werbel, LM | 3 |
| Worth, DF | 1 |
| Mathew, AE | 1 |
| Xu, PL | 1 |
| Northcutt, RV | 1 |
| Johnson, JL | 2 |
| Hoftiezer, JM | 1 |
| Leopold, WR | 2 |
| Shillis, JL | 1 |
| Jackson, RC | 3 |
| Elslager, EF | 2 |
| Petry, ME | 1 |
| Landi, JJ | 1 |
| Stallman, J | 1 |
| Polsenberg, JF | 1 |
| Gallagher, CE | 1 |
| Maresch, MJ | 1 |
| Giuliani, FC | 1 |
| Morier-Teissier, E | 1 |
| Boitte, N | 1 |
| Helbecque, N | 1 |
| Bernier, JL | 1 |
| Pommery, N | 1 |
| Duvalet, JL | 1 |
| Fournier, C | 1 |
| Hecquet, B | 1 |
| Catteau, JP | 1 |
| Hénichart, JP | 1 |
| Kolokythas, G | 1 |
| Kostakis, IK | 1 |
| Pouli, N | 1 |
| Marakos, P | 1 |
| Skaltsounis, AL | 1 |
| Pratsinis, H | 1 |
| Li, C | 1 |
| Zhao, X | 1 |
| Deng, C | 1 |
| Wang, C | 1 |
| Wei, N | 1 |
| Cui, J | 1 |
| Szmigielska-Kaplon, A | 1 |
| Ciesielska, E | 1 |
| Szmigiero, L | 1 |
| Robak, T | 1 |
| Verma, RP | 1 |
| Traganos, F | 1 |
| Evenson, DP | 1 |
| Staiano-Coico, L | 1 |
| Darzynkiewicz, Z | 2 |
| Melamed, MR | 1 |
| Fujimoto, S | 1 |
| Ogawa, M | 1 |
| Schabel, FM | 1 |
| Skipper, HE | 1 |
| Trader, MW | 1 |
| Brockman, RW | 1 |
| Laster, WR | 1 |
| Corbett, TH | 1 |
| Griswold, DP | 1 |
| Kimler, BF | 1 |
| Hazlehurst, LA | 2 |
| Kirshenbaum, MR | 1 |
| Chen, SF | 1 |
| Behrens, CH | 1 |
| Papp, LM | 1 |
| Stafford, MM | 1 |
| Sun, JH | 1 |
| Behrens, DL | 1 |
| Fredericks, JR | 1 |
| Polkus, ST | 1 |
| Sipple, P | 1 |
| Grabowski, D | 1 |
| Ganapathi, R | 1 |
| Chang, CW | 1 |
| Barber, L | 1 |
| Ouyang, C | 1 |
| Masin, D | 3 |
| Bally, MB | 3 |
| Madden, TD | 3 |
| Lim, HJ | 2 |
| Potemski, P | 1 |
| Polakowski, P | 1 |
| Parr, MJ | 1 |
| McIntosh, NL | 1 |
| Zhang, G | 1 |
| Johnstone, S | 1 |
| Niang, M | 1 |
| Mĕlka, M | 1 |
| Jin, G | 1 |
| You, Y | 1 |
| Ahn, B | 1 |
| Osswald, H | 2 |
| Frank, N | 1 |
| Schwendener, RA | 1 |
| Fiebig, HH | 1 |
| Berger, MR | 1 |
| Berger, DP | 1 |
| Morreal, CE | 1 |
| Bernacki, RJ | 1 |
| Hillman, M | 1 |
| Atwood, A | 1 |
| Cartonia, D | 1 |
| White, RJ | 1 |
| Durr, FE | 2 |
| Fry, DW | 1 |
| Boritzki, TJ | 1 |
| Besserer, JA | 1 |
| Wunz, TP | 1 |
| Dorr, RT | 1 |
| Alberts, DS | 3 |
| Tunget, CL | 1 |
| Einspahr, J | 1 |
| Milton, S | 1 |
| Remers, WA | 1 |
| Gewirtz, DA | 1 |
| Ellis, AL | 1 |
| Randolph, JK | 1 |
| Yanovich, S | 1 |
| Swerdlow, PS | 1 |
| Povirk, LF | 1 |
| Yalowich, JC | 1 |
| Youssef, M | 1 |
| Wang, BS | 1 |
| Ruszala-Mallon, V | 1 |
| Wallace, RE | 1 |
| Citarella, RV | 1 |
| Lin, YI | 1 |
| Burns, CP | 3 |
| Haugstad, BN | 2 |
| Mossman, CJ | 1 |
| North, JA | 3 |
| Ingraham, LM | 2 |
| Petersen, ES | 1 |
| Kapuscinski, J | 1 |
| Bowden, GT | 2 |
| Roberts, R | 1 |
| Peng, YM | 2 |
| Garcia, D | 1 |
| Dalton, WS | 1 |
| Mackel, C | 1 |
1 review available for mitoxantrone and Leukemia L 1210
| Article | Year |
|---|---|
Anti-cancer activities of 1,4-naphthoquinones: a QSAR study.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Humans; Hydrophobic and Hydrophilic I | 2006 |
44 other studies available for mitoxantrone and Leukemia L 1210
| Article | Year |
|---|---|
Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Leukemia L1210; Leukemia, Experim | 1979 |
Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cricetulus; DNA; | 1992 |
Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Hu | 1991 |
Synthesis and antineoplastic evaluation of 1,4-bis(aminoalkanamido)-9,10-anthracenediones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Survival; DNA; Leukemia L1210; Leukemia P388; M | 1988 |
Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cattle; Computer Simulation; Crystallography; DNA; D | 1988 |
Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; In Vitro Techniques; Indazoles; Leuke | 1988 |
Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
Topics: Animals; Anthraquinones; Leukemia L1210; Leukemia P388; Melanoma; Mitoxantrone; Structure-Activity R | 1987 |
Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
Topics: Animals; Anthracenes; Antineoplastic Agents; Drug Evaluation, Preclinical; Indicators and Reagents; | 1987 |
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Leukemia L1210; Leukemia P388; Mice; Mitoxantr | 1984 |
6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
Topics: Adenocarcinoma; Animals; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Humans; Isoquinol | 1994 |
Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Chelating Agents; Free Radicals; Leukemia L1210; Leu | 1993 |
Design and synthesis of some new pyranoxanthenone aminoderivatives with cytotoxic activity.
Topics: Acridines; Acronine; Animals; Antineoplastic Agents; Drug Design; Flow Cytometry; Fluorescence; HT29 | 2002 |
Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect.
Topics: Animals; Antineoplastic Agents; Ascitic Fluid; Dose-Response Relationship, Drug; Leukemia L1210; Lip | 2014 |
Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Cladribine; Doxorubicin; Idarubicin; Leukemia L | 2002 |
Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Cycle; Cell Survival; Cells, Cultured; Cricetinae; | 1980 |
Structure-activity relationship study of anthraquinones: 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethoxy)ethyl]amino]-9,10-anthracenedione, an analog of an established antineoplastic agent.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Leukemia L1210; Leukemia P388; Mice; Mitoxantrone; S | 1982 |
Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Resistance; Female | 1982 |
Drug control of Ara-C-resistant tumor cells.
Topics: 3-Deazauridine; Adenocarcinoma; Animals; Anthraquinones; Antimetabolites, Antineoplastic; Colonic Ne | 1982 |
Combination of dihydroxyanthraquinone and radiation on L1210 murine leukemia.
Topics: Animals; Anthracenes; Antineoplastic Agents; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Mitoxantr | 1981 |
Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Division; DNA Damage; DNA, Single-Stranded; Dru | 1995 |
Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Binding Sites; DNA, Neoplasm; Heterocyclic Compounds | 1995 |
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Colonic | 1994 |
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothe | 1996 |
Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice.
Topics: Animals; Injections, Intravenous; Leukemia L1210; Liposomes; Metabolic Clearance Rate; Mice; Mitoxan | 1997 |
Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Female; Leukemia L1210; Leukemia P388; Liposomes; Liv | 1997 |
Metoclopramide and nitrendipine are unable to enhance cytotoxicity of mitoxantrone in sensitive and resistant murine leukemias in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Drug Resistance, | 1997 |
Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.
Topics: Animals; Cholesterol; Dimyristoylphosphatidylcholine; Drug Carriers; Kupffer Cells; Leukemia L1210; | 2000 |
Effect of acetyl-L-carnitine on leukemia L1210 resistant to mitoxantrone.
Topics: Acetylcarnitine; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Leukemia L1210; Male; Mi | 2000 |
Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Disease Models, Animal; Esters; Leukemia L1210; Melp | 2001 |
Sacrosine- and prolinedithiocarbamate pretreatment increases the therapeutic efficacy of doxorubicin, methotrexate, teniposide, mitoxantrone or cyclohexylchloroethylnitrosourea in leukemia L1210.
Topics: Animals; Antineoplastic Agents; Cysteine; Doxorubicin; Drug Synergism; Female; Leukemia L1210; Lomus | 1990 |
Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Topics: Animals; Bone Marrow; Drug Carriers; Female; Half-Life; Humans; Leukemia L1210; Liposomes; Male; Mam | 1991 |
Antitumor properties of tetrahydrobenz[a]anthraquinone derivatives.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Chemical Phenomena; Chemistry; Ethanolamines; Humans | 1990 |
Development of mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Colonic Neopla | 1985 |
In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles).
Topics: Aminoacridines; Amsacrine; Animals; Anthraquinones; Colony-Forming Units Assay; DNA; Doxorubicin; Ki | 1985 |
New antitumor agents containing the anthracene nucleus.
Topics: Animals; Anthracenes; Cell Line; Chemical Phenomena; Chemistry; DNA; Humans; Leukemia L1210; Leukemi | 1987 |
Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization.
Topics: Animals; Cell Line; DNA Damage; DNA Replication; DNA Topoisomerases, Type II; DNA, Neoplasm; Endopep | 1989 |
Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.
Topics: Animals; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 1986 |
Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).
Topics: Adjuvants, Immunologic; Animals; Anthraquinones; Antineoplastic Agents; Cell Line; Colony-Stimulatin | 1986 |
Membrane lipid alteration: effect on cellular uptake of mitoxantrone.
Topics: Animals; Cell Membrane Permeability; Fatty Acids; Leukemia L1210; Membrane Lipids; Mice; Mitoxantron | 1988 |
Subcellular distribution of doxorubicin: comparison of fatty acid-modified and unmodified cells.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Doxorubicin; Fatty Acids; Leukemia L1210; Mitoxantr | 1988 |
Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Intercalating Agents; Leukemia L1210; Mice; Microsco | 1986 |
Membrane transport of mitoxantrone by L1210 leukemia cells.
Topics: Animals; Biological Transport; Cell Membrane; Cells, Cultured; Half-Life; Kinetics; Leukemia L1210; | 1987 |
Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
Topics: Animals; Anthracenes; Anthraquinones; Antineoplastic Agents; Cell Nucleus; Cell Survival; DNA, Neopl | 1985 |
Pharmacology of mitoxantrone: mode of action and pharmacokinetics.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Chromatography, High Pr | 1985 |